NASA Hitches Ride with SpaceX for StarBurst Satellite. Is RocketLab the Big Loser?

NASA just handed SpaceX another launch manifest slot, and the question for retirement-focused investors is direct: how do SpaceX (NASDAQ:SPCX | SPCX Price Prediction) and Rocket Lab (NASDAQ:RKLB) compare for retirement-focused portfolios after the StarBurst decision? The StarBurst satellite will fly on a Falcon 9 rideshare mission no earlier than 2028, and while the dollars are modest, rideshare keeps siphoning missions that might otherwise have gone to dedicated small-launch providers. That structural squeeze frames everything below.

Valuation: Premium Priced, but One Has Real Cash Flow

Both names trade at eye-watering multiples. SpaceX carries a 204x forward P/E, a price-to-sales ratio of 88.56, and an EV/EBITDA of 510. Rocket Lab looks cheaper on sales at a 52.96 price-to-sales, but its forward P/E sits at 1,111 and its EV/EBITDA is negative at -16 because EBITDA itself is negative.

The tiebreaker is quality of cash generation. SpaceX put up $3.54 billion in adjusted EBITDA last quarter, up 191% year over year, and sits on $93.5 billion in cash. Rocket Lab’s adjusted EBITDA loss narrowed to $8.8 million, an improvement, but still red ink. Winner: SPCX. Paying up for a franchise that already prints EBITDA beats paying up for one that doesn’t.

Growth Trajectory: Small Base, Bigger Percentage Runway

SpaceX grew Q2 revenue roughly 92% year over year to $7.81 billion, with the AI segment alone up 247% to $2.56 billion and Starlink subscribers doubling to 12 million. Backlog sits at $47.5 billion.

Rocket Lab grew 62% to $234.07 million and guided Q3 to $250 million to $265 million. Backlog jumped 137% to $2.36 billion, and CEO Peter Beck told analysts “the launch demand is extreme” and “launch has never been so constrained.” The Neutron medium-lift rocket is targeted for a Q4 2026 debut, and pending deals for Mynaric, Motiv, and Iridium widen the aperture materially.

Winner: RKLB. Off a $769 million TTM revenue base, Neutron plus the Iridium takeout offers more percentage torque than SpaceX can deliver at a $1.17 trillion market cap.

Volatility and Balance Sheet Risk: Not Even Close

Rocket Lab carries a beta of 2.612, has traded between a 52-week low of $37.57 and a high of $151, and just dropped 18.77% over the past month. Shareholders funded that ride with heavy dilution: $1.53 billion raised via ATM offerings in the first half of 2026 alone. Add Neutron execution risk (a prior stage 1 tank test failure delayed launch) and three simultaneous acquisition integrations, and the risk stack is dense.

SpaceX, freshly public, is volatile too, but the $93.5 billion cash pile and a $25 billion investment-grade bond issuance give it staying power no small-cap can match. Winner: SPCX.

Verdict for Retirement-Focused Investors

SpaceX wins two of three dimensions that matter for a long-horizon, capital-preservation-minded portfolio: valuation quality and downside protection. For a retiree or near-retiree researching space-economy exposure without funding a dilution treadmill, SPCX screens more favorably on cash flow and balance sheet metrics. The Barron’s read that AI demand keeps pulling SpaceX higher only reinforces the diversified-cash-machine thesis.

Rocket Lab wins one dimension outright, growth trajectory, and it wins it decisively. But that win belongs to a different investor: a younger, risk-tolerant buyer who can stomach a 2.6 beta, ATM dilution, and Neutron execution risk in exchange for a real shot at multi-bagger returns if Neutron flies clean. Retirement portfolios generally prioritize capital preservation over speculative upside. RKLB may warrant further research for investors focused on speculative growth exposure.

Contact [email protected] for any questions or corrections.